TCGA-A8-A099-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 10
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.480
- OXIDATIVE_PHOSPHORYLATION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.270
- ANDROGEN_RESPONSE+0.180
- FATTY_ACID_METABOLISM+0.180
- PEROXISOME+0.180
- UV_RESPONSE_DN+0.160
- HEME_METABOLISM+0.150
- PI3K_AKT_MTOR_SIGNALING+0.150
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
Top 10 suppressed
- E2F_TARGETS-0.390
- TNFA_SIGNALING_VIA_NFKB-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- ALLOGRAFT_REJECTION-0.300
- G2M_CHECKPOINT-0.290
- INFLAMMATORY_RESPONSE-0.260
- KRAS_SIGNALING_DN-0.260
- IL6_JAK_STAT3_SIGNALING-0.230
- MYOGENESIS-0.230
- APICAL_JUNCTION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5932-01A-11R-1755-07 | — | cohortA2 | 0.843 |
| 2 | MDT-AP-0397 | Med | Medulloblastoma | 0.824 |
| 3 | MDT-AP-0026 | Med | Medulloblastoma | 0.822 |
| 4 | MDT-AP-0044 | Med | Medulloblastoma | 0.813 |
| 5 | TCGA-E9-A1RD-01A-11R-A157-07 | — | B | 0.800 |
| 6 | MNG427 | — | — | 0.787 |
| 7 | TCGA-EW-A1OX-01A-11R-A144-07 | — | B | 0.784 |
| 8 | TCGA-D8-A1JI-01A-11R-A13Q-07 | — | B | 0.778 |
| 9 | BS_3F4FQJMR | EPN | Supratentorial EPN | 0.776 |
| 10 | TCGA-D8-A1JN-01A-11R-A13Q-07 | — | C | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |